It can be viewed as a battlefield where two forces—the “offensive” and the “defensive”—engage in continuous struggle: the “offensive” aims to eliminate tumors through strategies such as enhancing effector T cell and NK cell function (e.g., CAR-T (144) and CAR-NK therapies (145)) or releasing T cell suppression (e.g., using immune checkpoint inhibitors like anti-PD-1/PD-L1) (146); while the “defense” promotes tumor survival. The gene discussed is CD274; the disease is neoplasm.